Method of enhancing expression of MHC class I molecules...

Details Method of enhancing expression of MHC class I molecules... Method of enhancing expression of MHC class I molecules...

1997-07-21

2002-03-26

Schwartzman, Robert A. (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C435S325000, C435S320100, C514S04400A

Reexamination Certificate

active

06361770

ABSTRACT:

FIELD OF THE INVENTION
The invention relates generally to a method of enhancing expression of MHC class I molecules bearing endogenous peptides on the surface of a target cell and to a method of augmenting the immune response of a mammal to a tumor cell expressing low or nondetectable levels of MHC class I molecules bearing endogenous peptides. Further, the invention relates to a method of preparing tumor specific T cells which are therapeutically active against tumors.
BACKGROUND OF THE INVENTION
The cytotoxic T lymphocyte (CTL) response is a major component of the immune system, active in immune surveillance and destruction of infected or malignant cells and invading organisms expressing foreign antigens on their surface. The ligand of the antigen-specific T cell receptor is a complex made up of a peptide fragment of a foreign antigen bound to major histocompatibility complex (MHC) molecules. In particular, cytotoxic T lymphocytes recognise peptide bound to MHC Class I molecules.
MHC class I molecules are normally expressed at the cell surface as ternary complexes formed by a heavy chain of 46 kD, a light chain called &bgr;
2
-microglobulin (&bgr;
2
m) of 12 Kd and a peptide composed of 8-10 amino-acids (van Bleek, G. M. and S. G. Nathenson,
Nature
348:213, 1990; Zhang, W. et al.,
Proc. Natl. Acad. Sci. USA
89:8403, 1992; Matsumura, M. et al.,
Science
257:927, 1992; and Latron, F., et al., Science 257:964, 1992). Formation of the ternary complex is thought to involve transport into the lumen of the endoplasmic reticulum (ER) of peptides generated by protein degradation in the cytoplasm (Nuchtern, J. G. et al.,
Nature
339:223, 1989;Yewdell, J. W. and J. R. Bennink,
Science
244:1072, 1989; and Cox,
J. H. et al.,
Science
247:715, 1990). The study of mutant cell lines selected for their low expression of MHC class I molecules at the cell surface has provided insights into the molecular events required for antigen processing. These studies have allowed the identification of two genes located in the MHC region which encode proteins of the ATP binding cassette (ABC) family. These genes, called TAP-1 and TAP-2, have been implicated in transport of peptides from the cytoplasm to the lumen of the ER (Deverson, E. V. et al.,
Nature
348:738, 1990; Trowsdale, J. et al.,
Nature
348:741, 1990; Spies, T. et al.,
Nature
348:744, 1990; Monaco, J. J. et al.,
Science
250:1723, 1990; Spies, T. and R. DeMars,
Nature
351:323, 1991; Bahram, S. et al.,
Proc. Natl. Acad. Sci. USA
88:1009.4, 1991; Spies, T. et al.,
Nature
355:644, 1992; Kelly, A. et al.,
Nature
355:641, 1992; Powis, S. H. et al.,
Proc. Natl. Acad. Sci. USA
89:1463, 1992; and Colonna, M. et al.,
Proc. Natl. Acad. Sci. USA
89:3932, 1992). Two other MHC linked genes, LMP-2 and -7 (Monaco, J. J. and McDevitt, 1982
, Proc. Natl. Acad. Sci. USA
79:3001), are components of the proteasome, a cytoplasmic multicatalytic protease complex, which is likely responsible for some aspects of protein degradation for antigen processing (Ortiz-Navarette, V. et al.,
Nature
353:662, 1991; Brown, M. G. et al.,
Nature
353:355, 1991; Glynne, R. et al.,
Nature
353:357, 1991; Martinez, C. K. and J. J. Monaco,
Nature
353:664, 1991; Kelly, A. et al.,
Nature
353:667, 1991; Yang, Y. et al.,
Proc. Natl. Acad. Sci. USA
89:4928, 1992; Goldberg, A. L. and K. L. Rock,
Nature
357:375, 1992).
The mouse mutant lymphoma cell line RMA-S expresses low levels of class I molecules at the cell surface compared to the wild type RMA cells (Ljunggren, H.-G. et al.,
J. Immunol.
142:2911, 1989; and Townsend, A. et al.,
Nature
340:443, 1989). Influenza virus infected RMA-S cells present influenza peptides in the context of D
b
molecules inefficiently and are only weakly recognized by specific CTL (Townsend, A. et al.,
Nature
340:443, 1989). Transfection with the putative transporter gene, TAP-2, complements this deficiency (Powis, S. J. et al.,
Nature
354:528, 1991; and Attaya, M. et al.,
Nature
355:647, 1992). The endogenous TAP-2 gene of RMA-S cells was shown to contain a point mutation which introduces a stop translation codon resulting in an incomplete and defective TAP-2 protein (Yang, Y. et al.,
J. Biol. Chem.
267:11669, 1992). Despite the defective TAP-2 protein in RMA-S cells, antigenic peptides from vesicular stomatitis virus (VSV) bypass the defect and are presented to specific CTL by K
b
molecules in RMA-S cells (Esquivel, F., et al.,
J. Exp. Med.
175:163, 1992; and Hosken, N. A. and M. J. Bevan,
J. Exp. Med.
175:719, 1992). The VSV-nucleocapsid (N) peptide, VSV-N 52-59, has been shown to be the major peptide presented by K
b
molecules on VSV infected cells (van Bleek, G. M. and S. G. Nathenson,
Nature
348:213, 1990). The presence of the wild-type TAP-1 protein in RMA-S cells may be sufficient for translocation of the VSV-N 52-59 peptide to the ER lumen (Powis, S. J. et al.,
Nature
354:528, 1991; Attaya, M. et al.,
Nature
355:647, 1992; and Yang, Y. et al.,
J. Biol. Chem.
267:11669, 1992). Alternatively, the VSV-N 52-59 peptide may not need a functional transporter for transport into the lumen of the ER. Expression of minigene-encoded viral peptide epitopes in T2 cells (Zweerink, H. J. et al.,
J. Immunol.
150:1763, 1993) and in-vitro translation and translocation using microsomes from T2 cells (Levy, F. et al., Cell 67:265, 1991) support this contention.
A separate class of antigen processing variants are those in which the assembly and the surface expression of MHC class I molecules are entirely inducible by IFN-&ggr; (Klar, D. and G. J. Hämmerling,
EMBO J.
8:475, 1989). For example in the small lung carcinoma cell line, CMT.64, recognition by influenza virus specific CTL does not take place unless induced with IFN-&ggr; (Sibille, C. et al.,
Eur. J. Immunol.
22:433, 1992). The very low amount of all proteasome components present in uninduced CMT.64 cells is presumed to be responsible for their phenotype (Ortiz-Navarette, V. et al.,
Nature
353:662, 1991). Exogenous influenza peptides can bind to D
b
molecules on CMT.64 cells and complement recognition by influenza specific CTL (Sibille, C. et al.,
Eur. J. Immunol.
22:433, 1992). In addition, it has been found that the &bgr;
2
m and the VSV-N 52-59 peptides added exogenously to these cells complement recognition by VSV specific CTL restricted to K
b
(Jefferies W. A. et al., 1993
, J. Immunol.
151:2974). The amount of &bgr;2m and of heavy chains synthesized in these cells may limit the amount of MHC class I expression on the cell surface (Jefferies et al, supra, 1993). A dysfunction of the putative peptide transporters and/or in the generation of the peptide may be responsible for the CMT.64 phenotype which may represent a mechanism to downregulate MHC class I expression, a feature common to many carcinomas.
Restifo, N. R. et al. (
J. Exp. Med.
177:265-272, 1993) studied the antigen processing efficiency of 26 different human tumor lines using a recombinant vaccinia virus (Vac) to transiently express the K
d
molecule. Three cell lines, all human small cell lung carcinoma, consistently failed to process endogenously synthesized proteins for presentation to K
d
-restricted, Vac-specific T cells. Pulse-chase experiments showed that MHC class I molecules were not transported by the cell lines from the endoplasmic reticulum (ER) to the cell surface. Northern blot analysis of the cells revealed low to nondetectable levels of mRNAs for MHC-encoded proteasome components LMP-7 and LMP-2 as well as the putative peptide transporters TAP-1 and TAP-2.
SUMMARY OF THE INVENTION
The present inventors have surprisingly found that, despite the multiple antigen processing deficiencies in CMT.64 cells, TAP-1 transfected into the cells, alone was sufficient to induce CTL recognition of VSV infected cells in the absence of IFN-&ggr; induction. Importantly, TAP-1 was shown to function independently of TAP-2 in peptide transport, as the transfected cells remained negative for TAP-2 expression. It was also demonstrated that TAP-1 alone delivered specific peptide

Affiliated with

Also associated with

Rating

Method of enhancing expression of MHC class I molecules... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of enhancing expression of MHC class I molecules..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing expression of MHC class I molecules... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2868189